Research overview based on the cited scientific literature.

Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand[1][2].

Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Proper storage preserves peptide stability and potency.
Lyophilized: Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for months when frozen.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 4 weeks for optimal stability.
Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if needed to minimize temperature fluctuations.
Allow refrigerated vials to reach room temperature before opening to reduce condensation inside the vial.

SS31 (elamipretide) is a cellpermeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction[1]. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure[2][7]. By stabilizing cardiolipinprotein interactions, SS31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues[8].
Preclinical research demonstrated that SS31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemiareperfusion injury, neurodegeneration, chronic kidney disease, and agerelated muscle atrophy[9]. Clinical safety findings must be interpreted within each trial's formulation, enrolled population and observation period; they do not establish safety for research materials. Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints. FDA's 2025 label reports that the placebo-controlled Barth syndrome trial did not show superiority on its six-minute walk and fatigue primary endpoints. Muscle-strength increases were observed during the open-label extension. Forzinity received accelerated approval for improving muscle strength in patients with Barth syndrome weighing at least 30 kg; confirmatory evidence is required.

Observations from preclinical models and human clinical trials.
Potential Benefits:
Stabilizes mitochondrial membranes and optimizes electron transport chain function[1][2].
Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues[8].
The Barth syndrome findings and accelerated approval concern a specific medicinal product and indication. They do not establish general exercise benefits or equivalence of the research vials described here to the approved product.
Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and agerelated muscle atrophy[9].
Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials[4].
Common Side Effects:
The FDA label for the approved elamipretide product reports injection-site reactions and serious hypersensitivity reactions. Adverse-event rates and follow-up periods must be attributed to the specific study. Findings for an approved medicinal formulation should not be generalized to the research vials described here.